Home Tags SN-38

Tag: SN-38

Immunomedics and Everest Signs License Agreement for Sacituzumab Govitecan

In late April 2019 Immunomedics and Everest Medicines II Limited, a C-Bridge Capital-backed biopharmaceutical company, confirmed that the companies had signed an exclusive license...

New ADC Payload Platform – Synaffix Launches toxSYN™

The Netherlands-based biotech company Synaffix, which has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates or ADCs, launched of a...

Sacituzumab govitecan (IMMU-132) Demonstrates Therapeutic Potential in the Treatment of Metastatic...

Two prominent cancer journals have published phase II clinical trial results with sacituzumab govitecan (IMMU-132; Immunomedics) in a total of 104 patients with lung...

Peptide-drug Conjugates: Potent and Selective Miniaturized Conjugates for the Treatment of...

Targeted therapeutics, including antibody-drug conjugates ADCs, designed to  link targeted monoclonal antibodies, via a linker, to potent cell-killing payloads, have been a highly successful for creating...

New Patents Awarded for Immunomedics’ Antibody-drug Conjugates Development Program

Earlier this week Immunomedics announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent 9,492,566, the 32nd U.S. patent protecting the...

United States Patent and Trademark Office Awards New Patents to Immunomedics

Earlier this month the United States Patent and Trademark Office awarded U.S. Patent 9,458,242 to Immunomedics for additional claims under the patent family “Dosages of...

Enhancing Activity of Sacituzumab Govitecan in SN-38-Resistant Cancer

Adding an inhibitor of ATP-binding cassette (ABC) transporters to sacituzumab govitecan increased the median survival of mice bearing a SN-38-resistant human gastric cancer cell...

New U.S. Patent and Updated Clinical Development Plan for Sacituzumab Govitecan

Immunomedics, a clinical-stage biopharmaceutical company developing antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases, has received a new patent (U.S....

Breakthrough Therapy Designation for Sacituzumab Govitecan in Triple-negative Breast Cancer

Sacituzumab govitecan, also known as IMMU-132, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients...

Sacituzumab Govitecan Continues to show Positive Results in the Treatment of...

Updated results from a Phase II clinical study of sacituzumab govitecan, also known as IMMU-132, in patients with metastatic triple-negative breast cancer who had received...

FEATURED RESOURCES